A Phase 2 interventional study of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting, sponsored by Biogen. Completed at 12 sites in 10 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-10-23.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 15th largest by enrollment, is one of 6 that started in 2015, is one of 2 in phase 2, and was the 11th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2015.
This study's enrollment of 22 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 46th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2015, is one of 9 in phase 2, and was the 52nd registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of BG00012 (dimethyl fumarate) on brain magnetic resonance imaging (MRI) lesions in pediatric participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to characterize the pharmacokinetics of BG00012 in pediatric participants with RRMS and to evaluate the safety and tolerability of BG00012 in pediatric participants with RRMS.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
Drug: dimethyl fumarate
Also known as: BG00012, DMF
Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period
Time frame: Baseline Period (Week -8 to Day 0), On-Treatment Assessment Period (Week 16 to Week 24)
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 8
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Day 8
Apparent Clearance (CL/F)
Time frame: Day 8
Apparent Volume of Distribution (V/F)
Time frame: Day 8
Half-Life Lambda z
Time frame: Day 8
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf)
Time frame: Day 8
Number of Participants Who Experienced Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
Time frame: Up to Week 28
| Milestone | BG00012 |
|---|---|
| Started | 22 |
| Completed | 20 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
| lesions | BG00012 |
|---|---|
| Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period | -7.9 ± 16.23 |
| ng/mL | BG00012 |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 1998.62 ± 1286.467 |
| hours | BG00012 |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 4.20 ± 1.543 |
| L/h | BG00012 |
|---|---|
| Apparent Clearance (CL/F) | 74.45 ± 30.185 |
| L | BG00012 |
|---|---|
| Apparent Volume of Distribution (V/F) | 98.19 ± 91.679 |
| hours | BG00012 |
|---|---|
| Half-Life Lambda z | 0.84 ± 0.408 |
| h*mcg/mL | BG00012 |
|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) | 3630.52 ± 1153.768 |
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.
| participants | BG00012 |
|---|---|
| Any event | 20 |
| Moderate or severe event | 7 |
| Severe event | 1 |
| Event related to BG00012 | 16 |
| Serious event | 5 |
| Serious event related to BG00012 | 0 |
| Discontinued treatment due to an event | 2 |
| Withdrew from study due to an event | 2 |
Collected over From first dose of study drug through end of treatment period (Week 24 ±7 days) plus 4 weeks follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BG00012 | — | 5/22 (22.7%) | 19/22 (86.4%) |
| Event | BG00012 |
|---|---|
| Multiple sclerosis relapseNervous system disorders | 4/22 |
| VertigoEar and labyrinth disorders | 1/22 |
| Event | BG00012 |
|---|---|
| FlushingVascular disorders | 10/22 |
| Multiple sclerosis relapseNervous system disorders | 7/22 |
| Abdominal painGastrointestinal disorders | 6/22 |
| Abdominal pain upperGastrointestinal disorders | 4/22 |
| NauseaGastrointestinal disorders | 4/22 |
| HeadacheNervous system disorders | 4/22 |
| VomitingGastrointestinal disorders | 3/22 |
| FatigueGeneral disorders | 3/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/22 |
| VertigoEar and labyrinth disorders | 2/22 |
| Age, Continuous(years) | BG00012 |
|---|---|
| Mean | 15.8 ± 1.18 |
| Sex: Female, Male(Participants) | BG00012 |
|---|---|
| Female | 14 |
| Male | 8 |
Ran from Sep 2015 to primary completion in Sep 2016, 11 months.
Results were first posted in Apr 2017, 7 months after primary completion.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →